Dermatology Times

A leading news resource serving dermatology clinicians.

[Dermatology Times @DermTimesNow]

61% complete skin clearance at week 16 with high-dose ORKA-001 in psoriasis. See what else made October's dermatology headlines.

#Dermatology #DermNews

https://t.co/M0XdC5kRqF

[Dermatology Times @DermTimesNow]

📖 IN REVIEW: Updated hidradenitis suppurativa (HS) guidelines emphasize earlier intervention and the growing role of biologic therapies in managing moderate to severe disease.

Read more: https://t.co/za8w1k7c4k

#HidradenitisSuppurativa #HS #Biologics #Dermatology

[Dermatology Times @DermTimesNow]

💡 EXPERT INSIGHTS: Undertreating severe atopic dermatitis in children can have consequences that extend far beyond the skin.

Read more: https://t.co/m9YiB874wE

#AtopicDermatitis #PediatricDermatology #Eczema #Dermatology

[Dermatology Times @DermTimesNow]

🇺🇸 VETERANS DAY: Today, we honor the men and women who have served our country and recognize the lasting health challenges some veterans continue to face long after their service.

https://t.co/APoYBiCjGn

#VeteransDay #VeteransHealth #AgentOrange #Melanoma #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Brepocitinib achieved complete skin clearance in 69% of patients with cutaneous sarcoidosis, highlighting a potential new treatment approach for this difficult-to-manage condition.

https://t.co/FyjFnJGUjf

#Brepocitinib #CutaneousSarcoidosis #JAKInhibitors

[Dermatology Times @DermTimesNow]

61% complete skin clearance with ORKA-001. Zasocitinib outperforming deucravacitinib head to head.
October's top psoriasis, HS, and eczema stories in one recap ↓
https://t.co/7NQsud1nOc

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Litifilimab demonstrated improvements in clinician- and patient-reported skin symptoms through 52 weeks in patients with cutaneous lupus erythematosus (CLE).

Read more: https://t.co/Hkyrc5Vpfi

#Litifilimab #CutaneousLupus #Lupus #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: How do emerging oral psoriasis therapies compare when it comes to complete skin clearance?

Read more: https://t.co/MC8RSJVzae

#Psoriasis #OralTherapies #PASI100 #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Veradermics reported sustained hair growth through 1 year with investigational oral VDPHL01 in patients with androgenetic alopecia.

Read more: https://t.co/T5XVm3YXER

#VDPHL01 #AndrogeneticAlopecia #HairLoss #Dermatology

[Dermatology Times @DermTimesNow]

📈 NEW DATA: Bimekizumab demonstrated sustained joint responses through week 24 in patients with active psoriatic arthritis (PsA).

Read more: https://t.co/dyN3gmtBXq

#Bimekizumab #PsoriaticArthritis #Psoriasis #Dermatology

[Dermatology Times @DermTimesNow]

Join the community: https://t.co/AxYsuXdsuX

[Dermatology Times @DermTimesNow]

Your patients get your expertise. Your peers deserve it, too. Practicing dermatologist, NP, or PA? Share what you know as a roundtable moderator, podcast guest, writer, or on-camera expert.

Join the community: https://t.co/RfUqeKqA8g

[Dermatology Times @DermTimesNow]

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.
RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Clinician FAQ ↓
https://t.co/YM8UbYXa4l

[Dermatology Times @DermTimesNow]

🔔👥 CONFERENCE COVERAGE: Today, Dermatology Times is on-site in Philadelphia with Joel Gelfand, MD, MSCE, for DPEC: Dermatology in Pharma Educational Collaborative!

#DPEC2026 #DermatologyTimes #Dermatology #DermatologyResearch

[Dermatology Times @DermTimesNow]

📖 BETWEEN THE LINES: Remibrutinib is reshaping the treatment landscape for chronic inducible urticaria (CIndU).

Read more: https://t.co/Mw7LUAdWpr

#BetweenTheLines #Remibrutinib #ChronicInducibleUrticaria #Dermatology

[Dermatology Times @DermTimesNow]

✍⏳ THE PRACTICE BRIEF: New treatment options are expanding dermatologic care, but access barriers and evolving clinical guidance continue to shape everyday practice.

🔗 Read more: https://t.co/sZ79cHT1xT

#ThePracticeBrief #NPPAConnect #AdvancedPractice #Dermatology

[Dermatology Times @DermTimesNow]

💡 NPPA CONNECT: Nurse practitioners are making an impact far beyond the exam room. In recognition of National Nurse Practitioner Week, explore the growing influence of NPs across the profession.

https://t.co/O62TJlXQRY

#NPWeek #NursePractitioners #NPPAConnect #AdvancedPractice

[Dermatology Times @DermTimesNow]

Remibrutinib (Rhapsido) is now the first FDA-approved treatment for symptomatic dermographism.

RemIND: 29.3% complete hive response vs 14.0% with placebo at week 12.
Clinician FAQ ↓
https://t.co/IDWHdt3iTG

[Dermatology Times @DermTimesNow]

🚨 NEW TODAY: The American Academy of Dermatology Association (AADA) is warning of a potential 6% Medicare payment cut for dermatologists in 2027.

Read more: https://t.co/fNjdqhuK3M

#Medicare #Dermatology #HealthCarePolicy #PhysicianReimbursement

[Dermatology Times @DermTimesNow]

Lisa Swanson, MD, joins host Andrew Krakowski, MD, to discuss the often-overlooked impact of psoriasis on children’s quality of life in this episode of Don’t Be Rash, supported by Arcutis.

Watch the full episode here:

#PediatricPsoriasis #DontBeRash